Regeneron Pharmaceuticals (REGN) Convertible Debt (2011 - 2015)

Regeneron Pharmaceuticals has reported Convertible Debt for 5 years, with the latest figure at $30.7 million in Q3 2015.

• For the quarter ending Q3 2015, Convertible Debt fell 89.33% year-over-year to $30.7 million; the trailing twelve-month figure through Sep 2015 stood at $30.7 million (down 89.33% YoY), and the FY2014 full-year result was $146.8 million, down 54.18% from the prior year.
• Convertible Debt for Q3 2015 stood at $30.7 million, up from $30.4 million in the prior quarter.
• The five-year high for Convertible Debt was $326.7 million in Q1 2014, with the low at $30.4 million in Q2 2015.
• Average Convertible Debt over 5 years is $245.1 million, with a median of $286.7 million recorded in 2012.
• Year-over-year, Convertible Debt climbed 8.07% in 2014 and sank 89.33% in 2015.
• Tracing REGN's Convertible Debt over 5 years: stood at $275.0 million in 2011, then climbed by 7.82% to $296.5 million in 2012, then gained by 8.03% to $320.3 million in 2013, then tumbled by 54.18% to $146.8 million in 2014, then sank by 79.07% to $30.7 million in 2015.
• The last three Convertible Debt figures came in at $30.7 million (Q3 2015), $30.4 million (Q2 2015), and $144.1 million (Q1 2015), per Business Quant data.

Peer Comparison